You can buy or sell CLRB and other stocks, options, ETFs, and crypto commission-free!
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. Read More The company was founded in June,1996 and is headquartered in Florham Park, NJ.
Florham Park, New Jersey
52 Week High
52 Week Low
Cellectar Biosciences (CLRB) Announces FDA Exemption to Import Alert for CLR 131 in Pediatric and Adolescent Patients
Cellectar Biosciences, Inc. (NASDAQ: CLRB) today announced that the U.S. Food and Drug Administration (FDA) has granted an exemption to the Import Alert placed on the Centre for Probe Development and Commercialization (CPDC) for the use of CLR 131 in connection with the company’s pediatric IND. This exemption will allow Cellectar to immediately begin enrolling patients in its Phase 1 pediatric study for the treatment of select relapsed or refractory solid tumors including neuroblastoma, lymphomas and malign...
Simply Wall StMar 13
Does Market Volatility Impact Cellectar Biosciences, Inc.’s (NASDAQ:CLRB) Share Price?
If you’re interested in Cellectar Biosciences, Inc. (NASDAQ:CLRB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first category is company specific volatility. This can be dealt with by limiting your exposure to any particular stock. The other type, which cannot be diversified away, is the ...
Markets InsiderFeb 26
Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update
FLORHAM PARK, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2018, and provided a corporate update. Fourth Quarter and Recent Corporate Highlights Announced additional positive top-line results from the relapse refractory multiple myeloma cohort in its ongoing Pha...
Expected May 9, Pre-Market